Advancing Toward Clinical Trials

Clinical Progress

MTX-531 demonstrates exceptional promise in preclinical development

Development Timeline

From preclinical validation to first-in-human clinical trials

2022-2023

Preclinical Development

Comprehensive preclinical studies demonstrating exceptional efficacy and tolerability in monotherapy...

  • Durable tumor regressions across multiple PDX histologies
  • Complete regressions observed in HNSCC models
  • Unprecedented preclinical activity using clinically relevant endpoints
  • No hyperglycemia, body weight loss, or other clinical signs of toxicity
July 2024

Nature Cancer Publication

Groundbreaking research published validating MTX-531's mechanism and preclinical results

Read Full Publication
2023-2025

IND-Enabling Studies Complete

Comprehensive regulatory and development activities in partnership with NCI NExT Program

  • Good Laboratory Practice (GLP) toxicology studies
  • Pharmacokinetics and ADME characterization
  • Chemistry, Manufacturing, and Controls (CMC) development
  • Clinical protocol design and regulatory strategy
  • Drug substance and drug product manufacturing scale-up
May 2026

IND Approved

Investigational New Drug application cleared by FDA

  • All IND-enabling studies completed
  • CMC documentation finalized
  • Clinical trial protocols approved
  • Regulatory submission package complete
Mid-2026 (Target)

First-in-Human Clinical Trial

Phase I clinical trial initiation anticipated for mid-2026

  • Safety and tolerability assessment
  • Dose escalation studies
  • Preliminary efficacy signals
  • Target patient populations: Head and neck, breast, endometrial, colon, PIK3CA mutant cancers

NCI NExT Program Partnership

MEKanistic is partnering with the National Cancer Institute's Experimental Therapeutics (NExT) Program to accelerate the development of MTX-531 toward clinical trials. This milestone-driven collaboration provides critical support for IND-enabling studies.

Explore Our Market Opportunity

Discover the cancer types we're targeting with MTX-531

View Market Opportunity